First Quadrant’s 9 Meters Biopharma NMTR Stock Holding History

First Quadrant’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,185	Closed	-$55K	–	843
2018 Q4	$55K	Hold	1,185	–	–	﹤0.01%	723
2018 Q3	$162K	Buy	+1,185	New	+$204K	﹤0.01%	650

Other funds holding NMTR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

First Quadrant's NMTR Position: Q1 2019 in Review

First Quadrant sold out of 9 Meters Biopharma (NMTR) in Q1 2019, closing a stake of 1,185 shares — an estimated $55K sold.

First Quadrant first reported a position in NMTR in Q3 2018 and held it in 2 quarters. The position peaked at $162K in Q3 2018. 38 funds tracked by Wall St. Rank hold NMTR as of Q1 2019.

First Quadrant reported no remaining 9 Meters Biopharma position as of Q1 2019 after selling out during the quarter.
First Quadrant sold 1,185 9 Meters Biopharma shares in Q1 2019, an estimated $55K.
First Quadrant first reported a position in 9 Meters Biopharma in Q3 2018 and held it in 2 quarters.
First Quadrant's 9 Meters Biopharma position peaked at $162K in Q3 2018.
38 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q1 2019.

Based on First Quadrant's 13F filing for Q1 2019, filed 24 Apr 2019.